Home/Pipeline/Undisclosed Peripheral

Undisclosed Peripheral

Cardiometabolic Disease

Pre-clinicalActive

Key Facts

Indication

Cardiometabolic Disease

Phase

Pre-clinical

Status

Active

Company

Manifold Bio

About Manifold Bio

Manifold Bio is a private, preclinical-stage biotech based in Cambridge, MA, founded in 2019. The company has developed a unique platform that integrates AI-guided protein design with direct, high-throughput in vivo testing to engineer biologics with precise tissue-targeting properties. Its initial pipeline focuses on CNS-targeted therapies for Alzheimer's and Parkinson's diseases, with a broader vision to build a 'virtual organism' predictive model. The company is backed by notable investors and has entered a strategic collaboration with Roche.

View full company profile

Therapeutic Areas

Alzheimer's Disease Parkinson's Disease Cardiometabolic Disease

Other Cardiometabolic Disease Drugs

Drug	Company	Phase	Status
PCSK9 Program	nChroma Bio	Candidate-Enabled	Active
PCSK9 Multiplex Program	nChroma Bio	Research	Active
Undisclosed (Cardiometabolic)	SanegeneBio	Phase 1	Active